The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent recently gained FDA approval for COPD, marking its sixth U.S. indication since its first use for atopic dermatitis ...

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks.

Chronic obstructive pulmonary disease (COPD) burden remains high in underdeveloped regions of China despite a decline in ...

Power capacity and infrastructure are vital to China’s green transition and hi-tech ambitions, but ‘power abandonment’ is a critical setback. New deep-sea mobile operation can reportedly ...